Health X Platform growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+18.8%−19.2%+32.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+7.0%−1,134.6%+112.3%
+5.1%−1,561.7%+92.9%
+98.9%−2,381.8%+105.9%
+101.3%−1,127.2%+112.3%
−4.0%−15.2%−4.7%
−11.5%−13.5%+0.6%
−326.5%−145.4%+136.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HEALTHX₹279.20

Health X Platform Limited

· Pharma & Health
₹ CrorePeersSURAKSHAKRSNAANEPHROPLUS3BBLACKBIOMcap ₹888 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+32.3-19.2+18.8—
EBITDA Growth—+112.3-1,134.6+7.0—
EBIT Growth—+92.9-1,561.7+5.1—
Net Income Growth—+105.9-2,381.8+98.9—
EPS Growth—+112.3-1,127.2+101.3—
Total Assets Growth—-4.7-15.2-4.0—
Total Equity Growth—+0.6-13.5-11.5—
Cash from Operations Growth—+136.5-145.4-326.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.